权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Pharmacology of nonsteroidal androgen receptor ligands

非甾体雄激素受体配体的药理学

基本信息

批准号：
7267607
负责人：
JAMES T DALTON
金额：
$ 32.71万
依托单位：
OHIO STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2000
资助国家：
美国
起止时间：
2000-09-30 至 2008-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7267607
关键词：
Agonist American Androgen Antagonists Androgen Receptor Androgens Animals Bicalutamide Black race Cell Line Chemicals Class Data Depth Disease Drug Exposure Drug Kinetics Drug or chemical Tissue Distribution Endocrine Esters Exposure to Fertility Gene Expression Genes Goals Grant In Vitro International Laboratories Lead Learning Ligands Male Contraceptions Malignant neoplasm of prostate Metabolism Minerals Muscle Oxidoreductase Pathway interactions Pattern Pharmaceutical Preparations Pharmacologic Actions Pharmacologic Substance Pharmacology Physiological Progress Reports Prostate Relative (related person)Reporting Research Research Personnel Role Seminal Vesicles Societies Spermatogenesis Steroids Structure-Activity Relationship Testing Testosterone Therapeutic Therapeutic Agents Tissues Work Yin bone dalton day design in vivo innovation interest male molecular modeling novel novel strategies pharmacophore programs receptor binding selective androgen receptor modulator size symposium

项目摘要

DESCRIPTION (provided by applicant): This is a competing application to continue our studies of the pharmacology of nonsteroidal androgen receptor (AR) ligands. The long-term hypothesis of our research is that orally active nonsteroidal androgens will mimic the beneficial in vivo endocrine and pharmacologic effects of testosterone, while avoiding undesirable effects. In the first three years of this grant, we advanced our hypothesis from a set of promising in vitro data to definitive in vivo studies showing that selective androgen receptor modulators (SARMs) represent an emerging new class of therapeutic agents with potential use in most androgen-related disorders. Studies will build upon existing expertise and test 3 independent yet closely related hypotheses: 1. Hypothesis 1: Novel pharmacophores will demonstrate potent in vitro and in vivo pharmacologic effects. The SARMs discovered in our laboratories are close structural relatives of bicalutamide. This raises the question as to whether other nonsteroidal antiandrogen platforms can be structurally optimized to act as androgen agonists. These studies are a continuation of the aims of our previous grant with a refined focus on the conformational structural requirements for ligand-AR interactions. 2. Hypothesis 2: SARMs mimic the endocrine and pharmacologic effects of exogenously administered testosterone. Data presented in our progress report indicate that unique structure-activity relationships exist for regulating endocrine and testicular function. We will continue to explore this promising lead as a foray into new approach to male contraception. 3. Hypothesis 3: Steroidal and nonsteroidal androgens regulate identical gene expression patterns in the prostate, but differ in potency. Microarray studies completed in our laboratory suggest that observed differences in tissue-selectivity (i.e., the ability to maintain prostate and muscle size) are a result of differences in pharmacologic potency, tissue amplification (e.g., 5a-reductase), or drug exposure.

描述（由申请人提供）：这是一个竞争性申请，以继续我们对非甾体雄激素受体（AR）配体的药理学研究。我们研究的长期假设是，口服活性非甾体雄激素将模仿睾酮的有益体内内分泌和药理作用，同时避免不良影响。在这项资助的前三年，我们将我们的假设从一组有希望的体外数据推进到明确的体内研究，表明选择性雄激素受体调节剂（SARMs）代表了一种新兴的新型治疗药物，在大多数雄激素相关疾病中具有潜在的用途。研究将建立在现有专业知识的基础上，并检验3个独立但密切相关的假设：假设1：新型药效团将在体内和体外表现出强大的药理作用。在我们的实验室中发现的sarm是比卡鲁胺的近亲。这就提出了一个问题，即其他非甾体抗雄激素平台是否可以在结构上优化作为雄激素激动剂。这些研究是我们之前资助目标的延续，重点关注配体- ar相互作用的构象结构要求。2. 假设2:SARMs模拟外源性睾酮的内分泌和药理作用。在我们的进展报告中提出的数据表明，独特的结构-活性关系存在于调节内分泌和睾丸功能。我们将继续探索这一有希望的线索，作为男性避孕新方法的尝试。3. 假设3：甾体和非甾体雄激素调节前列腺中相同的基因表达模式，但效力不同。我们实验室完成的微阵列研究表明，观察到的组织选择性差异（即维持前列腺和肌肉大小的能力）是药理学效力、组织扩增（如5a-还原酶）或药物暴露差异的结果。

项目成果

期刊论文数量（33）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

Interspecies differences in pharmacokinetics and metabolism of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethylphenyl)-propionamide: the role of N-acetyltransferase.

S-3-(4-乙酰氨基-苯氧基)-2-羟基-2-甲基-N-(4-硝基-3-三氟甲基苯基)-丙酰胺的药代动力学和代谢的种间差异：N-乙酰转移酶的作用。

DOI：
10.1124/dmd.105.007120
发表时间：
2006
期刊：
Drug metabolism and disposition: the biological fate of chemicals
影响因子：
0
作者：
Gao,Wenqing;Johnston,JeffreyS;Miller,DuaneD;Dalton,JamesT
通讯作者：
Dalton,JamesT

Preclinical pharmacology of a nonsteroidal ligand for androgen receptor-mediated imaging of prostate cancer.

用于雄激素受体介导的前列腺癌成像的非甾体配体的临床前药理学。

DOI：
10.1124/jpet.105.094334
发表时间：
2006
期刊：
The Journal of pharmacology and experimental therapeutics
影响因子：
0
作者：
Yang,Jun;Bohl,CaseyE;Nair,VipinA;Mustafa,SuniM;Hong,SeoungSoo;Miller,DuaneD;Dalton,JamesT
通讯作者：
Dalton,JamesT

In vivo metabolism and final disposition of a novel nonsteroidal androgen in rats and dogs.

新型非甾体雄激素在大鼠和狗体内的体内代谢和最终处置。